| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
240,015 |
105,990 |
$31.42M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
216,515 |
104,044 |
$5.94M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
47,821 |
30,585 |
$3.37M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
45,044 |
44,602 |
$2.28M |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
24,826 |
15,357 |
$733K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
18,027 |
13,584 |
$357K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,007 |
1,222 |
$112K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,621 |
1,317 |
$111K |
| 87634 |
|
2,010 |
1,222 |
$93K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
4,507 |
4,168 |
$80K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,477 |
2,450 |
$69K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,509 |
1,972 |
$41K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
4,103 |
2,052 |
$38K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,444 |
1,981 |
$37K |
| 87428 |
|
984 |
937 |
$32K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
374 |
299 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
68 |
68 |
$1K |
| 87430 |
|
696 |
671 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
97 |
93 |
$364.01 |
| 81003 |
|
275 |
261 |
$197.37 |
| 99051 |
|
5,053 |
3,736 |
$173.00 |
| 87400 |
|
84 |
82 |
$161.65 |
| 81025 |
|
78 |
77 |
$145.10 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
72 |
69 |
$143.02 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15 |
15 |
$96.00 |
| 99072 |
|
65 |
45 |
$90.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
23 |
21 |
$46.80 |
| 99401 |
|
12 |
12 |
$32.01 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
36 |
33 |
$0.56 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
17 |
16 |
$0.00 |
| 99050 |
|
129 |
116 |
$0.00 |